Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on UTHR stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roanna Ruiz’s rating is based on the promising results from United Therapeutics’ TETON-2 trial, which demonstrated that Tyvaso has a significant treatment effect when added to standard care for idiopathic pulmonary fibrosis (IPF). The trial showed a clinically meaningful improvement in forced vital capacity (FVC) compared to placebo, positioning Tyvaso as a potentially groundbreaking add-on therapy. This is particularly notable as the benefits were observed on top of existing antifibrotic therapies, suggesting a unique role for Tyvaso in the IPF treatment landscape.
Moreover, the inhaled delivery method of Tyvaso provides a safety advantage by targeting the lungs directly, potentially reducing side effects compared to other treatments like Ofev and Esbriet. The trial also indicated positive secondary outcomes, such as improved quality of life and reduced clinical worsening, which could expand its applicability to a broader patient population. These factors, combined with the potential for commercial expansion into the large US IPF market, underpin the Buy rating given by Roanna Ruiz.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $459.00 price target.
Based on the recent corporate insider activity of 143 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.